Literature DB >> 22356776

Cancer biomarkers.

N Lynn Henry1, Daniel F Hayes.   

Abstract

Biomarkers have many potential applications in oncology, including risk assessment, screening, differential diagnosis, determination of prognosis, prediction of response to treatment, and monitoring of progression of disease. Because of the critical role that biomarkers play at all stages of disease, it is important that they undergo rigorous evaluation, including analytical validation, clinical validation, and assessment of clinical utility, prior to incorporation into routine clinical care. In this review we address key steps in the development of biomarkers, including ways to avoid introducing bias and guidelines to follow when reporting results of biomarker studies.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22356776      PMCID: PMC5528374          DOI: 10.1016/j.molonc.2012.01.010

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  42 in total

Review 1.  Cancer biomarkers.

Authors:  N Lynn Henry; Daniel F Hayes
Journal:  Mol Oncol       Date:  2012-02-06       Impact factor: 6.603

2.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Authors:  Susan M Domchek; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Gabriella Pichert; Laura Van t'veer; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Wendy S Rubinstein; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joellen Schildkraut; Joanne L Blum; Timothy R Rebbeck
Journal:  JAMA       Date:  2010-09-01       Impact factor: 56.272

Review 3.  Clinical trial designs for predictive marker validation in cancer treatment trials.

Authors:  Daniel J Sargent; Barbara A Conley; Carmen Allegra; Laurence Collette
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

4.  Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.

Authors:  Federico Innocenti; Mark J Ratain
Journal:  Pharmacogenomics       Date:  2006-12       Impact factor: 2.533

5.  Linkage of early-onset familial breast cancer to chromosome 17q21.

Authors:  J M Hall; M K Lee; B Newman; J E Morrow; L A Anderson; B Huey; M C King
Journal:  Science       Date:  1990-12-21       Impact factor: 47.728

6.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

7.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

Authors:  Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes
Journal:  N Engl J Med       Date:  2004-08-19       Impact factor: 91.245

8.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D F Easton; D Ford; D T Bishop
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

9.  Sources of bias in specimens for research about molecular markers for cancer.

Authors:  David F Ransohoff; Margaret L Gourlay
Journal:  J Clin Oncol       Date:  2009-12-28       Impact factor: 44.544

10.  The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group.

Authors:  Steven M Teutsch; Linda A Bradley; Glenn E Palomaki; James E Haddow; Margaret Piper; Ned Calonge; W David Dotson; Michael P Douglas; Alfred O Berg
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822

View more
  158 in total

Review 1.  Cancer biomarkers.

Authors:  N Lynn Henry; Daniel F Hayes
Journal:  Mol Oncol       Date:  2012-02-06       Impact factor: 6.603

2.  Challenges for quality management in implementation, maintenance, and sustainability of research tissue biobanks.

Authors:  S Schmitt; K Kynast; P Schirmacher; E Herpel
Journal:  Virchows Arch       Date:  2015-08-14       Impact factor: 4.064

Review 3.  The changing landscape of phase I trials in oncology.

Authors:  Kit Man Wong; Anna Capasso; S Gail Eckhardt
Journal:  Nat Rev Clin Oncol       Date:  2015-11-10       Impact factor: 66.675

4.  Multiplex Immunosensor Arrays for Electrochemical Detection of Cancer Biomarker Proteins.

Authors:  Bernard S Munge; Thomas Stracensky; Kathleen Gamez; Dimitri DiBiase; James F Rusling
Journal:  Electroanalysis       Date:  2016-06-07       Impact factor: 3.223

5.  Using Clinical PK/PD Studies to Support No Clinically Meaningful Differences Between a Proposed Biosimilar and the Reference Product.

Authors:  Peijuan Zhu; Ping Ji; Yaning Wang
Journal:  AAPS J       Date:  2018-08-09       Impact factor: 4.009

Review 6.  Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer-Current Use and Future Opportunities.

Authors:  Lara Paracchini; Maurizio D'Incalci; Sergio Marchini
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

Review 7.  Assessment of Laser Effects on Skin Rejuvenation.

Authors:  Hazhir Heidari Beigvand; Mohammadreza Razzaghi; Mohammad Rostami-Nejad; Majid Rezaei-Tavirani; Saeed Safari; Mostafa Rezaei-Tavirani; Vahid Mansouri; Mohammad Hossein Heidari
Journal:  J Lasers Med Sci       Date:  2020-03-15

8.  Dually functional polyethylenimine-coated gold nanoparticles: a versatile material for electrode modification and highly sensitive simultaneous determination of four tumor markers.

Authors:  Thitirat Putnin; Aroonsri Ngamaroonchote; Natta Wiriyakun; Kontad Ounnunkad; Rawiwan Laocharoensuk
Journal:  Mikrochim Acta       Date:  2019-04-27       Impact factor: 5.833

9.  Tumor Targeting via Sialic Acid: [68Ga]DOTA-en-pba as a New Tool for Molecular Imaging of Cancer with PET.

Authors:  Charalambos Tsoukalas; Simonetta Geninatti-Crich; Anastasios Gaitanis; Theodoros Tsotakos; Maria Paravatou-Petsotas; Silvio Aime; Rogelio Jiménez-Juárez; Constantinos D Anagnostopoulos; Kristina Djanashvili; Penelope Bouziotis
Journal:  Mol Imaging Biol       Date:  2018-10       Impact factor: 3.488

Review 10.  Clinical analysis and interpretation of cancer genome data.

Authors:  Eliezer M Van Allen; Nikhil Wagle; Mia A Levy
Journal:  J Clin Oncol       Date:  2013-04-15       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.